We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » UK’s NICE Weighs In on Cardiac Therapies, Recommends Novel Migraine Treatment
The item has been added to your shopping cart.
UK’s NICE Weighs In on Cardiac Therapies, Recommends Novel Migraine Treatment
The UK’s healthcare cost-benefit watchdog is recommending implantable cardioverter defibrillators as a first-line treatment for people with previous serious ventricular arrhythmia, those with a familial cardiac condition with a high risk of sudden death and patients who have undergone surgical repair of congenital heart disease.
To View This Article:
Login
Subscribe To International Medical Device Regulatory Monitor